BITX (formerly IRX)

BITX (formerly IRX) is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer.

BITX (formerly IRX) is developing novel immunotherapies based upon reversing immune suppression typically seen in patients with cancer and other diseases by activating and stimulating multiple components of the cellular immune system. BITX’s extensive research science leads us to believe this will result in immune system recognition of and activation against disease.

BITX’s lead product, IRX-2, is a primary cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.

News from Disruptive Capital Finance